| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Atezolizumab-induced autoimmune haemolytic anaemia caused by drug-independent antibodies
|
Chambers, Bradley S.
|
|
|
162 |
C |
p. 158-160
|
artikel
|
| 2 |
Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer
|
Shirasawa, Masayuki
|
|
|
162 |
C |
p. 1-10
|
artikel
|
| 3 |
Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox
|
Bayle, Arnaud
|
|
|
162 |
C |
p. 128-129
|
artikel
|
| 4 |
Cancer immunotherapy efficacy is driven by tumour biology, not by its histology. Impact on drug development and approvals
|
Bonvalet, Mélodie
|
|
|
162 |
C |
p. 130-132
|
artikel
|
| 5 |
Changing characteristics, treatment approaches and survival of patients with brain metastasis: data from six thousand and thirty-one individuals over an observation period of 30 years
|
Steindl, Ariane
|
|
|
162 |
C |
p. 170-181
|
artikel
|
| 6 |
Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis
|
Goldinger, Simone M.
|
|
|
162 |
C |
p. 22-33
|
artikel
|
| 7 |
Circulating tumour DNA sequencing to determine therapeutic response and identify tumour heterogeneity in patients with paediatric solid tumours
|
Stankunaite, Reda
|
|
|
162 |
C |
p. 209-220
|
artikel
|
| 8 |
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma
|
Lechner, Matt
|
|
|
162 |
C |
p. 221-236
|
artikel
|
| 9 |
Corrigendum to ‘Age-related differences of oncological outcomes in primary extremity soft tissue sarcoma: a multistate model including 6260 patients’ [Eur J Cancer 141 (2020) 128-136]
|
Acem, Ibtissam
|
|
|
162 |
C |
p. 247-249
|
artikel
|
| 10 |
Corrigendum to “Conceptual framework for precision cancer medicine in Germany: Consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy’” [European Journal of Cancer 135 (2020) 1-7]
|
Benedikt Westphalen, C.
|
|
|
162 |
C |
p. 245-246
|
artikel
|
| 11 |
Dose finding of oncolytic combination therapy: Essential to secure the patient's quality of life
|
Wuyts, Stephanie C.
|
|
|
162 |
C |
p. 237-240
|
artikel
|
| 12 |
First case of a melanocytic intrabulbar brain tumour treated with bevacizumab
|
Skayem, Charbel
|
|
|
162 |
C |
p. 206-208
|
artikel
|
| 13 |
Hypersensitivity to Pegylated E.coli asparaginase as first-line treatment in contemporary paediatric acute lymphoblastic leukaemia protocols: a meta-analysis of the Ponte di Legno Toxicity working group
|
Brigitha, Leiah J.
|
|
|
162 |
C |
p. 65-75
|
artikel
|
| 14 |
Immunotherapy in older patients with hepatocellular carcinoma
|
Lyu, Ning
|
|
|
162 |
C |
p. 76-98
|
artikel
|
| 15 |
Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study
|
Baciarello, Giulia
|
|
|
162 |
C |
p. 56-64
|
artikel
|
| 16 |
Interval breast cancer is associated with interferon immune response
|
Ugalde-Morales, Emilio
|
|
|
162 |
C |
p. 194-205
|
artikel
|
| 17 |
Regorafenib–avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial
|
Cousin, Sophie
|
|
|
162 |
C |
p. 161-169
|
artikel
|
| 18 |
Reply to: Letter comments on: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers
|
Schadendorf, Dirk
|
|
|
162 |
C |
p. 243-244
|
artikel
|
| 19 |
Re: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers
|
Hersey, Peter
|
|
|
162 |
C |
p. 241-242
|
artikel
|
| 20 |
Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies
|
Stouvenot, Morgane
|
|
|
162 |
C |
p. 138-147
|
artikel
|
| 21 |
Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies
|
Keller, Kaylee M.
|
|
|
162 |
C |
p. 107-117
|
artikel
|
| 22 |
T cell immune awakening in response to immunotherapy is age-dependent
|
Salih, Zena
|
|
|
162 |
C |
p. 11-21
|
artikel
|
| 23 |
The PanCareFollowUp Care Intervention: A European harmonised approach to person-centred guideline-based survivorship care after childhood, adolescent and young adult cancer
|
van Kalsbeek, Rebecca J.
|
|
|
162 |
C |
p. 34-44
|
artikel
|
| 24 |
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article
|
Barrière, Jérôme
|
|
|
162 |
C |
p. 182-193
|
artikel
|
| 25 |
Towards an EU legislation on the right to be forgotten to access to financial services for cancer survivors
|
Scocca, Grazia
|
|
|
162 |
C |
p. 133-137
|
artikel
|
| 26 |
Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations
|
Iwama, Eiji
|
|
|
162 |
C |
p. 99-106
|
artikel
|
| 27 |
Treatment strategies for thymic carcinoma in a real-life setting. Insights from the RYTHMIC network
|
Petat, Arthur
|
|
|
162 |
C |
p. 118-127
|
artikel
|
| 28 |
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer—findings from the RIBECCA trial
|
Peuker, Caroline A.
|
|
|
162 |
C |
p. 45-55
|
artikel
|
| 29 |
UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients
|
Hulshof, Emma C.
|
|
|
162 |
C |
p. 148-157
|
artikel
|
Tijdschrift beschrijving